Latest Placebo-controlled study Stories
LYNBROOK, N.Y., Oct. 12 /PRNewswire/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that its partner Auxilium Pharmaceuticals, Inc. (Auxilium) has dosed the first subject in the global Phase 3 program of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of Peyronie's disease. Peyronie's disease is the development of scar tissue on the shaft of the penis that can cause the...
BOCA RATON, Fla., Oct. 12 /PRNewswire/ -- Smart for Life(R), the trailblazing company featuring weight management products will begin adding Lepticore(R) to its product line this month. Lepticore(R) has been created by a leading pharmaceutical research company which has conducted randomized, double-blind, placebo-controlled human clinical trials, which is considered the "Gold Standard" in product efficacy validation, and has appeared in the peer-reviewed journal Lipids in Health and...
MOUNTAIN VIEW, Calif., Sept. 8 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX(TM). In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX. At this time, all patients have been enrolled in the Company's...
RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced positive Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA), held in Orlando, FL from June 25-29, 2010. Data from Sangamo's SB-509-601 and SB-509-701B Phase 2 clinical trials demonstrated that SB-509 treatment resulted in clinically...
ANN ARBOR, Mich., June 15 /PRNewswire-FirstCall/ -- Adeona Pharmaceuticals, Inc. (Amex: AEN) announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, has expanded its in-house diagnostic testing services to include a full array of microbiology testing. Adeona believes that that this expansion of services will be accretive to HartLab's revenues in the current quarter and beyond and is consistent with Adeona's plans to continue to build the revenues of its HartLab...
STOCKHOLM, June 15, 2010 /PRNewswire-FirstCall/ -- After only one week of supplementation the reduction in daily crying time was 74 % among the infants supplemented by L. reuteri Protectis compared to 38 % in the placebo group. At the end of the study there was a significant difference between the two groups. (Logo: http://www.newscom.com/cgi-bin/prnh/20100615/394961 ) - These results are in line with previous studies on colics and confirm the benefit of L. reuteri in colicky...
NEW YORK, May 27 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial's independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules....
SAN DIEGO, May 17 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. today announced the presentation of data from its Phase 2b clinical trial with Aeroquin(TM) (a proprietary aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF) at the American Thoracic Society (ATS) Annual Meeting in New Orleans. Trial results demonstrated statistically significant improvements in bacterial load, respiratory function and time to need for anti-pseudomonal antibiotics (a measure of exacerbations)...
Completion occurs 5 months ahead of schedule TSX Exchange Symbol: RVX CALGARY, May 12 /PRNewswire-FirstCall/ - Resverlogix is pleased to announce that the Phase 2 ASSERT clinical trial for its lead drug, RVX-208, a small molecule therapy for the treatment of atherosclerosis has now completed dosing. "The completion of dosing for our Phase 2 ASSERT trial, five months ahead of schedule and without any alterations to the dose levels of the three drug receiving cohorts, is another major step...
A trial in Ghana has shown that vitamin A supplementation does not reduce maternal mortality"”contradicting previous findings from a trial in Nepal which showed a 44% decrease. The new study (ObaapaVitA) is reported online and in an upcoming edition of The Lancet and has been written by Professor Betty R Kirkwood, Professor in Epidemiology & International Health and colleagues in the Department of Nutrition and Public Health Intervention Research at the London School of Hygiene and...
